254 related articles for article (PubMed ID: 27384149)
1. Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
Kawashiri SY; Nishino A; Suzuki T; Nakashima Y; Horai Y; Ueki Y; Aramaki T; Fujikawa K; Nakashima M; Okada A; Migita K; Mizokami A; Matsuoka N; Mine M; Sakito S; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Eguchi K; Kawakami A
Clin Exp Rheumatol; 2016; 34(5):808-812. PubMed ID: 27384149
[TBL] [Abstract][Full Text] [Related]
2. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
3. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.
Maldonado-Montoro M; Cañadas-Garre M; González-Utrilla A; Plaza-Plaza JC; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():264-271. PubMed ID: 27339827
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M
Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
[TBL] [Abstract][Full Text] [Related]
5. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
[TBL] [Abstract][Full Text] [Related]
6. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Origuchi T; Ueki Y; Migita K; Mizokami A; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):370-4. PubMed ID: 21240618
[TBL] [Abstract][Full Text] [Related]
7. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.
Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf R; Hall C; Proudman SM; Wiese MD
Int J Rheum Dis; 2017 May; 20(5):576-583. PubMed ID: 26692459
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients.
Nakajima T; Watanabe R; Hashimoto M; Murata K; Murakami K; Tanaka M; Ito H; Yamamoto W; Kitagori K; Akizuki S; Nakashima R; Yoshifuji H; Ohmura K; Matsuda S; Morinobu A
Rheumatol Int; 2022 Nov; 42(11):1983-1991. PubMed ID: 34241658
[TBL] [Abstract][Full Text] [Related]
9. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
11. Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab.
Hoshi D; Nakajima A; Shidara K; Seto Y; Tanaka E; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2013 Nov; 23(6):1205-10. PubMed ID: 23456321
[TBL] [Abstract][Full Text] [Related]
12. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
Mod Rheumatol; 2014 Jan; 24(1):17-25. PubMed ID: 24261754
[TBL] [Abstract][Full Text] [Related]
13. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
Mori S; Yoshitama T; Abe Y; Hidaka T; Hirakata N; Aoyagi K; Ueki Y
Rheumatology (Oxford); 2019 Jul; 58(7):1274-1284. PubMed ID: 30793749
[TBL] [Abstract][Full Text] [Related]
14. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI.
Kaneko A; Kida D; Saito K; Tsukamoto M; Sato T
Rheumatol Int; 2012 Nov; 32(11):3631-7. PubMed ID: 22127466
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.
Narváez J; Magallares B; Díaz Torné C; Hernández MV; Reina D; Corominas H; Sanmartí R; LLobet JM; Rodriguez de la Serna A; Nolla JM
Semin Arthritis Rheum; 2016 Feb; 45(4):386-90. PubMed ID: 26254548
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
[TBL] [Abstract][Full Text] [Related]
17. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
[TBL] [Abstract][Full Text] [Related]
18. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
Gossec L; Steinberg G; Rouanet S; Combe B
Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
[TBL] [Abstract][Full Text] [Related]
19. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.
Cannon GW; Wang BC; Park GS; Koenig A; Collier DH; Keystone EC
Clin Exp Rheumatol; 2013; 31(6):919-25. PubMed ID: 24237999
[TBL] [Abstract][Full Text] [Related]
20. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]